




ImmunoACT

Newsletter

Making CAR-T affordable
and accessible




Highlights

ImmunoACT is making breakthrough in the field of haemato-oncology, having completed Phase I clinical trials in 2022 on our lead CAR-T candidate (HCAR19) in strategic partnership with Tata Memorial Center, Mumbai; the summary results were presented at The American Society of Hematology (ASH) annual meeting 2022, New Orleans. [learn more](#)

Pivotal (Phase II/ III) multi-center clinical trials for r/r B-cell malignancies are underway (since January 2023) in accordance with regulatory advice provided by the DCGI.

The Govt. of Mexico and affiliated institutions (IPN/ INCMNSZ) have entered into a strategic partnership with ImmunoACT with the goal of expanding access of HCAR19 in Mexico. [read more](#)

We are delighted to welcome two torchbearers in global CGTs, Dr. Nirali Shah, MD and Dr. Sattva Neelapu, MD to our Scientific Advisory Board. [know more](#)



ImmunoACT

"Make-in-India" Going Global



His Excellency - Mr. Marcelo Ebrard Casaubon - Secretary of Foreign Affairs visited ImmunoACT's GMP at MIDC Rabale, Navi Mumbai to learn about our gene-modified cell therapy against B-cell malignancies, a CD19-targeting CAR-T cell therapy. A MOU is signed between ImmunoACT and the Mexican Government - Instituto Nacional De Ciencias Medicas Y Nutricion salvadir Zubiran (INCMNSZ) and Instituto Politecnico Nacional (IPN) to make the first of these treatments, accessible and affordable to patients in Mexico.

Read more on >



Glimpses




For more



Contact Us : helpdesk@immunoact.com

Follow us on :





ImmunoACT

We are proud to announce the Expansion of Our Scientific Advisory Board



Dr. Nirali Shah

**Lasker Research
Investigator at the NCI's
Paediatric Oncology
branch of the NIH, USA**

[Know more](#)

Dr. Sattva Neelapu

**Professor, MD Anderson
Cancer Center, USA**

[Know more](#)



OUR EXISTING BOARD MEMBERS



Dr. Carl June



Dr. Avery Posey



Dr. Gaurav Narula





ImmunoACT

Innovative Research on Display: ImmunoACT's presentation at American Society Of Hematology (ASH)



ASH is the world's largest professional society of hematology, the members of which are working to conquer blood diseases, with more than 18,000 members across nearly 100 countries

ImmunoACT's aim is to improve access to life-saving CGTs in limited resource settings, beginning with India. To achieve this goal, we developed a robust, scalable, fully indigenous, highly affordable and accessible CAR-T cell therapy platform. Our product and process development, as well as our first-in-human clinical study with Tata Memorial Center, Mumbai thus far has provided early signs of better safety and efficacy.

Our platform has the potential to benefit a broader socio-economic base of patients. We believe that cell and gene therapy is at the frontier of a mission to improve the overall quality of life of patients with critical illnesses.

To know more >




First-in-human clinical trial




Discover our insights

Glimpses



Dr. Atharva Karulkar (Co-founder and Head -Scientific Programs- ImmunoACT)



From left : Dr. Carl June with Dr. Rahul Purwar (CEO- ImmunoACT)



From left: Dr. Rizwan Romee - Assoc. Prof. Dana Faber Cancer Institute




From left : Dr. Hasmukh Jain (TMH) and Dr. Terry Fry (Sana Biotech)

Contact Us : helpdesk@immunoact.com

Follow us on :






ImmunoACT

Featured Showcase



Showcasing our work at
IIT Bombay to
UN Secretary-General –
Mr. Antonio Guterres



Sonali Acharjee
New Delhi, ISSUE DATE: Oct 3, 2022 | UPDATED: Sep 25, 2022 16:01 IST



Illustrations by Nilanjan Das

When Rahul Purwar returned to India in 2013 after training at Harvard Medical School in immunotherapy, a branch of precision or customised oncology that uses the body's own immune system to prevent, control and eliminate cancer cells, he found the protocol entirely missing in the country. "There were only three options for patients—chemotherapy, radiation or surgery. If these didn't work, you had no other choice—cancer was your death sentence," he says. Yet, exciting trials on immunotherapy in the US, China, Israel and Europe were establishing it as a technology with the potential to cure cancer. "India had a far greater need for a cure because the country has more cases, but new treatments were being offered in other countries," he adds.


Featured as a cover story in India Today October 2022 Edition

[know more](#)

Contact Us : helpdesk@immunoact.com

Follow us on :





ImmunoACT

Sharing our expertise at Various Forums

Be sure to catch ImmunoACT on KBC for an insightful look at the future of cancer treatment and to explain the impact of cell & gene therapy for the masses

[Watch here](#)





We were honored to participate as a panel member at the ET Re Pharma Summit in Mumbai in March 2023. Our Director, Shirish Arya, discussed our journey from discovery to market and the opportunities and challenges faced by biotech startups in India. The summit explored how India can become a global hub for innovation in biological drugs.

BioAsia 2023:

"Exploring the potential of CAR-T cell therapy" with Rahul Purwar, as he explains how innovative technology is transforming healthcare.

[Watch here](#)





In Media



Minister Ebrard tweets about the developments in cancer treatment with CAR-T Therapy coming to Mexico.

[Watch more on >](#)



It's Coming Home:

Homegrown CAR-T cells 'cure' 8-year-old's leukemia

[Read more on >](#)



Listen to our Podcast:
ImmunoACT Advances Plans For
Cut-Price CAR-T In India

[Read more on >](#)



Pharma Intelligence

Cutting-edge treatments to cure cancer now affordable and accessible :
ImmunoACT leading towards making affordable cell and gene therapies in India

[Read more on >](#)





ImmunoACT

Follow us for Exclusive Content



Follow us on :



Contact Us : helpdesk@immunoact.com

Immunoadoptive Cell Therapy Pvt Ltd :

Address: 1st Floor, Plot, R-977, T.T.C. Industrial Area, MIDC Industrial Area, Rabale, Navi Mumbai, Maharashtra 400701